logo-loader

Lexaria Bioscience inks US partnership to produce CBD beverages

Last updated: 08:40 07 May 2019 EDT, First published: 08:30 07 May 2019 EDT

Cannabis leaf in a cup of tea
The Kelowna, British Columbia company also announced it would issue 790,000 stock options

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) is dishing out its signature infusion technology to build a better cannabidiol beverage.

Through its subsidiary Lexaria Hemp Corp, the company is pairing its DehydraTECH system with a Nevada-based private company to create CBD beverages for sale in the US.

DehydraTECH is the company’s method of delivering anything from vitamins to nicotine to CBD in order to maximize absorption, speed and taste.

READ: Lexaria Bioscience welcomes four new experts to advisory board to guide ongoing research

The deal is expected to last five years, although no financial details nor the company’s name, was disclosed.

The Kelowna, British Columbia company also announced it would issue 790,000 stock options to directors, an offer and its employees at an exercise price of C$0.99 per share.

Lexaria is focused on developing healthier ingestion methods and fast-acting, pleasant-tasting products. DehydraTECH is patented in the US and Australia, and the company has patents pending in 40 countries.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Lexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drug

Lexaria BioScience CEO Chris Bunka joined Steve Darling from Proactive to share significant updates regarding its focus on DehydraTECH, a patented drug delivery formulation and processing platform technology aimed at improving the oral delivery of active pharmaceutical ingredients. Lexaria...

1 week, 3 days ago